HWAM
NTLA icon

Hennion & Walsh Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Hennion & Walsh Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73M Buy
220,523
+60,720
+38% +$850K 0.11% 242
2026
Q1 		$2.05M Sell
159,803
-6,918
-4% -$88.1K 0.07% 345
2025
Q4 		$1.5M Buy
166,721
+16,328
+11% +$225K 0.05% 410
2025
Q3 		$2.6M Sell
150,393
-2,757
-2% -$34K 0.09% 277
2025
Q2 		$1.44M Buy
153,150
+6,684
+5% +$54.9K 0.06% 397
2025
Q1 		$1.04M Buy
146,466
+25,469
+21% +$257K 0.05% 464
2024
Q4 		$1.41M Buy
120,997
+67,276
+125% +$1.05M 0.06% 380
2024
Q3 		$1.1M Buy
53,721
+13,839
+35% +$319K 0.05% 428
2024
Q2 		$893K Buy
+39,882
New +$950K 0.05% 449

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Hennion & Walsh Asset Management's NTLA Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Intellia Therapeutics (NTLA) stake by 38% in Q2 2026, buying an estimated $850K and bringing the position to 220,523 shares worth $3.73M. The position accounts for 0.11% of the portfolio, ranked #242.

Hennion & Walsh Asset Management first reported a position in NTLA in Q2 2024 and has held it in 9 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Hennion & Walsh Asset Management held 220,523 shares of Intellia Therapeutics worth $3.73M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 60,720 Intellia Therapeutics shares in Q2 2026, an estimated $850K.
  • Intellia Therapeutics made up 0.11% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #242 holding.
  • Hennion & Walsh Asset Management first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.